


DARE-19

#ACC21



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Hospitalized patients with COVID-19 were randomized in a 1:1 fashion to either dapagliflozin 10 mg daily or placebo. Patients were followed for 90 days.



RESULTS

- Primary endpoint, organ failure or death, for dapagliflozin vs. placebo: 11.2% vs. 13.8% ($p = 0.17$)
- Composite kidney endpoint: 7.7% vs. 10.4% (HR 0.74, 95% CI 0.50-1.07)
- All-cause mortality: 6.6% vs. 8.6% ($p > 0.05$)

CONCLUSIONS

- Dapagliflozin did not significantly reduce organ dysfunction or death or improve recovery compared with placebo among noncritically ill hospitalized patients with COVID-19
- Patients with and without DM2 were included and very few patients had baseline HF or CKD

Presented by Dr. Mikhail Kosiborod at ACC.21